Skip to content

A Clinical trial to study the effect of the drug Atropine in patients with myopia to slow down its progression.

The effect of low dose Atropine on progression of myopia.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045977
Enrollment
280
Registered
2022-09-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H521- Myopia

Interventions

Intervention1: 0.01% Atropine Eyedrops.: one drop in each eye once at night for 2 years. Control Intervention1: Single Vision Spectacles versus Single Vision Spectacles plus Low dose Atropine: Atropin

Sponsors

Comtrust Charitable trust Eye Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Myopic patients of 6â??13 year age group, Refractive error of -1.0 D to -6.0 D, Associated astigmatism of -1.5 D or less, Documented myopic progression of at least 0.5 D in the past year

Exclusion criteria

Exclusion criteria: Any other additional eye pathology other than myopia, Previous use of Atropine Eye drops, an allergy to atropine, or systemic ill health (e.g., cardiac or respiratory illness)

Design outcomes

Primary

MeasureTime frame
To study the change in spherical equivalent refractive error and axial length in patients on low dose atropine for mild to moderate myopia To compare the effect of low dose atropine plus single vision spectacles versus single vision spectacles only(control) on myopia progression Timepoint: 2 years

Secondary

MeasureTime frame
To study the risk factors contributing to the progression of myopia, To evaluate the side effect parameters associated with low dose AtropineTimepoint: 2 years

Countries

India

Contacts

Public ContactDr Leila Mohan

Comtrust Charitable Trust Eye Hospital

leilamohan@hotmail.com9447244224

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026